Rachelle Gent

Ms. Rachelle Gent

Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
LBLise Barnard
Lise Barnard
Rachelle GentRachelle Gent
Rachelle Gent
DRDesmaré van Rooyen
Desmaré van Rooyen
ASAmanda Swart
Amanda Swart


1 April 2018 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
DRDesmaré van Rooyen
Desmaré van Rooyen
Rachelle GentRachelle Gent
Rachelle Gent
LBLise Barnard
Lise Barnard
ASAmanda Swart
Amanda Swart

29 July 2022 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
KKK.H. Kothmann
K.H. Kothmann
AJA. Jons
A. Jons
BWB. Wilhelmi
B. Wilhelmi
Nasser KasoziNasser Kasozi
Nasser Kasozi
LGL. Graham
L. Graham
ANAnnie Newell-Fugate
Annie Newell-Fugate


Verified
Journal Article
Open access
PDF file
Rachelle GentRachelle Gent
Rachelle Gent
DRDesmaré van Rooyen
Desmaré van Rooyen
SAStephen L Atkin
Stephen L Atkin
ASAmanda Swart
Amanda Swart
C11-oxy C19 and C11-oxy C21 steroids have been identified as novel steroids but their function remains unclear. This study aimed to investigate the pre-receptor regulation of C11-oxy steroids by 11β-hydroxysteroid dehydrogenase (11βHSD) interconversion and potential agonist and antagonist activity associated with the androgen (AR) and progesterone receptors (PRA and PRB). Steroid conversions were investigated in transiently transfected HEK293 cells expressing 11βHSD1 and 11βHSD2, while CV1 cells were utilised for agonist and antagonist assays. The conversion of C11-hydroxy steroids to C11-oxo steroids by 11βHSD2 occurred more readily than the reverse reaction catalysed by 11βHSD1, while the interconversion of C11-oxy C19 steroids was more efficient than C11-oxy C21 steroids. Furthermore, 11-ketodihydrotestosterone (11KDHT), 11-ketotestosterone (11KT) and 11β-hydroxydihydrotestosterone (11OHDHT) were AR agonists, while only progestogens, 11β-hydroxyprogesterone (11βOHP4), 11β-hydroxydihydroprogesterone (11βOHDHP4), 11α-hydroxyprogesterone (11αOHP4), 11α-hydroxydihydroprogesterone (11αOHDHP4), 11-ketoprogesterone (11KP4), 5α-pregnan-17α-diol-3,11,20-trione (11KPdione) and 21-deoxycortisone (21dE) exhibited antagonist activity. C11-hydroxy C21 steroids, 11βOHP4, 11βOHDHP4 and 11αOHP4 exhibited PRA and PRB agonistic activity, while only C11-oxo steroids, 11KP4 and 11-ketoandrostanediol (11K3αdiol) demonstrated PRB agonism. While no steroids antagonised the PRA, 11OHA4, 11β-hydroxytestosterone (11OHT), 11KT and 11KDHT exhibited PRB antagonism. The regulatory role of 11βHSD isozymes impacting receptor activation is clear—C11-oxo androgens exhibit AR agonist activity; only C11-hydroxy progestogens exhibit PRA and PRB agonist activity. Regulation by the downstream metabolites of active C11-oxy steroids at the receptor level is apparent—C11-hydroxy and C11-oxo metabolites antagonize the AR and PRB, progestogens the former, androgens the latter. The findings highlight the intricate interplay between receptors and active as well as “inactive” C11-oxy steroids, suggesting novel regulatory tiers.